Vera Therapeutics (VERA) | Stock Overview & Key Data
Vera Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $21.45
High: $22.65
on August 21, 2025
52 Week Range
Low: $18.53
High: $51.61
on April 9, 2025
on November 13, 2024
All-Time High: $51.61 on November 11, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.4B
EPS
-3.59
P/E Ratio (TTM)
-8.04
Forward P/E
-7.05
P/B Ratio
2.99
PEG Ratio
-0.09
Div. Yield
N/A
ROE
-54.84%
Beta
1.166
Debt to Equity
16.56
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-30.24%
Return on Equity (TTM)
-54.84%
EBITDA
$-235.8M
Net Income (TTM)
$-218.3M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Vera Therapeutics VERA | 1.40B Small-cap | 6.30% | -0.79% | 10.89% | -20.89% | -46.42% | -42.47% | 15.12% | 96.61% |
| Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
| Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
| Cg Oncology CGON | 1.99B Small-cap | 0.08% | -3.42% | -0.92% | -6.71% | -10.32% | -29.82% | -25.83% | -25.83% |
| Adaptive ADPT | 1.99B Small-cap | -2.24% | 22.50% | 38.94% | 52.72% | 104.04% | 159.88% | 20.52% | -69.05% |
| Vericel VCEL | 1.80B Small-cap | -0.92% | -0.06% | -13.71% | -31.85% | -35.69% | -28.10% | 30.92% | 116.49% |
Ownership & Short Interest
Insider Ownership
3.96%
Institutional Ownership
109.90%
Shares Short
8M
Short Ratio
7.96
Short % of Shares Outstanding
13.67%
Average 10-Day Volume
1M
Average 90-Day Volume
1M
Vera Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Vera Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is VERA's 52-week high and low?
- In the last 52 weeks, Vera Therapeutics reached a high of $51.61 (on November 13, 2024) and a low of $18.53 (on April 9, 2025).
- What is the market cap and P/E ratio for VERA?
- Curious about Vera Therapeutics's size and valuation? Its market capitalization stands at 1.40B. When it comes to valuation, the P/E ratio (trailing twelve months) is -8.04, and the forward P/E (looking ahead) is -7.05.
- Does VERA pay dividends? If so, what's the yield?
- As for dividends, Vera Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Vera Therapeutics's main competitors or similar companies to consider before investing?
When looking at Vera Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% Cg Oncology
CGON1.99B Healthcare Biotechnology -29.82% -25.83% Adaptive
ADPT1.99B Healthcare Biotechnology 159.88% 20.52% Vericel
VCEL1.80B Healthcare Biotechnology -28.10% 30.92% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Vera Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Vera Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -54.84%, the Debt to Equity ratio from the most recent quarter is 16.56, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for VERA?
- Looking at Vera Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of VERA stock is held by insiders and institutions?
- Wondering who owns Vera Therapeutics stock? Company insiders (like executives and directors) hold about 3.96% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.90%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.